HIV-1 protease inhibitors.

@article{Eron2000HIV1PI,
  title={HIV-1 protease inhibitors.},
  author={Joseph J Eron},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2000},
  volume={30 Suppl 2},
  pages={
          S160-70
        }
}
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro. PIs with 2 nucleoside analogue reverse transcriptase inhibitors have demonstrated prolonged suppression of HIV-1 replication in treated patients and improvements in disease progression and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

“In vitro” Antifungal activity of protease inhibitors

  • Mycopathologia
  • 2001
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 97 REFERENCES

HIV-protease inhibitors.

  • The New England journal of medicine
  • 1998
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogues in human immunodeficiency virus–infected persons with CD4 cell counts <200 per cubic millimeter

SM Hammer, K Squires, M Hughes
  • N Engl J Med
  • 1997
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

ABT-378/ritonavir (ABT-387/r) suppresses HIV RNA to !400 copies/mL in 95% of treatment-naive patients and in 78% of PI-experienced patients at 36 weeks [abstract LB20

J Eron, M King, Y Xu
  • Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)
  • 1999
VIEW 2 EXCERPTS

Amprenavir (141W94, APV)/3TC/ ZDV exerts durable antiviral acitivity in HIV-1–infected antiretroviral therapy–naive subjects through 48 weeks of therapy [abstract 509

J Goodgame, C Hanson, I Vafidis
  • Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)
  • 1999
VIEW 2 EXCERPTS

BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers [abstract 604

EM O’Mara, J Smith, +3 authors S. Kaul
  • Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health,
  • 1999
VIEW 1 EXCERPT

Combination of I592/141W94 therapy in HIV-1–infected antiretroviral therapy–naive subjects with CD41 counts greater than 400 cells/microliter and viral load greater than 5000 copies/mL [abstract 365

PA Bart, GP Rizzardi, S Gallant
  • Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health,
  • 1999
VIEW 1 EXCERPT